Department of Pharmaceutics, School of Pharmaceutical Sciences and ‡First Affiliated Hospital, Wenzhou Medical University , Wenzhou City, Zhejiang Province 325035, China.
ACS Appl Mater Interfaces. 2017 Sep 6;9(35):29580-29594. doi: 10.1021/acsami.7b10211. Epub 2017 Aug 24.
Hydrogel was not only used as an effective support matrix to prevent intrauterine adhesion after endometrial injury but also served as scaffold to sustain release of some therapeutics, especially growth factor. However, because of the rapid turnover of the endometrial mucus, the poor retention and bad absorption of therapeutic agents in damaged endometrial cavity were two important factors hindering their pharmacologic effect. Herein, a mucoadhesive hydrogel was described by using heparin-modified poloxamer (HP) as the matrix material and ε-polylysine (EPL) as functional excipient. Various EPL-HP hydrogels formulations are screened by rheological evaluation and mucoadhesion studies. It was found that the rheological and mucoadhesive properties of EPL-HP hydrogels were easily controlled by changing the amount of EPL in formulation. The storage modulus of EPL-HP hydrogel with 90 μg/mL of EPL (EPL-HP-90) was elevated to be 1.9 × 10 Pa, in accordance with the adhesion force rising to 3.18 N (10-fold higher than HP hydrogels). Moreover, in vitro release of model drug keratinocyte growth factor (KGF) from EPL-HP hydrogel was significantly accelerated by adding EPL in comparison with HP hydrogel. Both strong mucoadhesive ability and the accelerated drug release behavior for EPL-HP-90 made more of the encapsulated KGF absorbed by the uterus basal layer and endometrial glands after 8 h of administration in uterus cavity. Meanwhile, the morphology of endometrium in the injured uterus was repaired well after 3 d of treatment with KGF-EPL-HP-90 hydrogels. Compared with KGF-HP group, not only proliferation of endometrial epithelial cell and glands but also angiogenesis in the regenerated endometrium was obviously enhanced after treatment with KGF-EPL-HP-90 hydrogels. Alternatively, the cellular apoptosis in the damaged endometrium was significantly inhibited after treatment with KGF-EPL-HP-90 hydrogels. Overall, the mucoadhesive EPL-HP hydrogel with a suitable KGF release profile may be a more promising approach than HP hydrogel alone to repair the injured endometrium.
水凝胶不仅可以作为一种有效的支撑基质,防止子宫内膜损伤后发生宫腔粘连,还可以作为支架,持续释放一些治疗药物,尤其是生长因子。然而,由于子宫内膜黏液的快速周转,治疗药物在受损的子宫内膜腔中的保留和吸收不良是两个重要的阻碍其药效的因素。在此,本文通过使用肝素修饰的泊洛沙姆(HP)作为基质材料和 ε-聚赖氨酸(EPL)作为功能赋形剂来描述一种具有黏膜黏附性的水凝胶。通过流变学评价和黏膜黏附研究筛选了各种 EPL-HP 水凝胶配方。结果发现,通过改变配方中 EPL 的用量,EPL-HP 水凝胶的流变学和黏膜黏附性能很容易得到控制。含 90 μg/mL EPL 的 EPL-HP 水凝胶(EPL-HP-90)的储能模量升高到 1.9×10 Pa,与之对应的黏附力增加到 3.18 N(比 HP 水凝胶高 10 倍)。此外,与 HP 水凝胶相比,EPL 的加入显著加速了模型药物角质细胞生长因子(KGF)从 EPL-HP 水凝胶中的体外释放。EPL-HP-90 具有较强的黏膜黏附能力和加速药物释放行为,使更多包裹的 KGF 在给药 8 小时后被子宫基底层和子宫内膜腺体吸收。同时,在宫腔内给予 KGF-EPL-HP-90 水凝胶治疗 3 d 后,受损子宫的子宫内膜形态得到了很好的修复。与 KGF-HP 组相比,KGF-EPL-HP-90 水凝胶治疗后,子宫内膜上皮细胞和腺体的增殖以及再生子宫内膜的血管生成明显增强,而受损子宫内膜的细胞凋亡明显受到抑制。总之,具有合适 KGF 释放特性的黏膜黏附性 EPL-HP 水凝胶可能比 HP 水凝胶单独使用更有希望修复受损的子宫内膜。